Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Terminated Phase 3 Interventional Results available

One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

NCT02240121
View directory record Official record
Conditions
Crohn's Disease
Interventions
Rifaximin EIR, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
72
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 23, 2026, 3:17 PM EDT
Withdrawn Not applicable Interventional

Microbiome Modification to Enhance Stelara Response in Crohn's Disease

NCT04795960
View directory record Official record
Conditions
Crohn Disease
Interventions
Low serine diet, High serine diet
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 23, 2026, 3:17 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

NCT03269695
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06687234, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Dothan, Alabama • Atlanta, Georgia • Chevy Chase, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 23, 2026, 3:17 PM EDT
Completed Phase 1Phase 2 Interventional

STA-5326 in Crohn's Disease Patients

NCT00088062
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Tucson, Arizona • Anaheim, California • North Miami Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 3:17 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lutikizumab, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
48
States / cities
Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 23, 2026, 3:17 PM EDT
Completed No phase listed Observational

Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis

NCT01301417
View directory record Official record
Conditions
Diverticulum, Colon, Colorectal Neoplasms, Crohn Disease, Colitis, Ulcerative, Colostomy, Ileostomy - Stoma, Rectal Prolapse, Intestinal Polyposis, Lymphoma, Endometriosis, Intestinal Volvulus
Interventions
ColonRing™
Device
Lead sponsor
novoGI
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Riverdale, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 23, 2026, 3:17 PM EDT
Completed No phase listed Observational

Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

NCT05584735
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Influenza vaccine, COVID-19 vaccine
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 23, 2026, 3:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation Between Central Sensitization Inventory and Posturographic Data

NCT03058003
View directory record Official record
Conditions
Central Nervous System Sensitization
Interventions
Posturography Evaluation, Central Sensitization Inventory
Diagnostic Test · Other
Lead sponsor
Caps Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Recruiting No phase listed Observational

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

NCT02103361
View directory record Official record
Conditions
Psoriasis, Pregnancy, Psoriatic Arthritis, Crohn Disease
Interventions
Ustekinumab, Guselkumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 3:17 PM EDT
Completed Not applicable Interventional

Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients

NCT03550742
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Fuco-N-Tetraose
Other
Lead sponsor
Glycom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 23, 2026, 3:17 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT01988961
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
La Jolla, California • National City, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 23, 2026, 3:17 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GutMe!: IBS and Collagen Protein Powder an Interventional Study

NCT04245254
View directory record Official record
Conditions
Irritable Bowel Syndrome, Irritable Bowel, Irrit
Interventions
Collagen Protien Powder
Dietary Supplement
Lead sponsor
ProofPilot
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 23, 2026, 3:17 PM EDT
Completed Early Phase 1 Interventional

Fecal Microbiota Transplant for Inflammatory Bowel Disease

NCT02460705
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Biologically active human fecal material, OpenBiome
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 23, 2026, 3:17 PM EDT
Withdrawn Phase 3 Interventional

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT04612803
View directory record Official record
Conditions
Irritable Bowel Syndrome, Dermatographism, Post-prandial Diarrhea
Interventions
Antihistamine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

NCT01053962
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg, SP-304 9.0 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
14
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 23, 2026, 3:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Observational Pharmaco-Epidemiology Research & Analysis

NCT03813862
View directory record Official record
Conditions
Chronic Disease, HIV/AIDS, Liver Diseases, Inflammatory Bowel Diseases, Cardiovascular Diseases, Rheumatic Diseases, Neurodegenerative Diseases
Interventions
Non-interventional (observational only)
Other
Lead sponsor
Epividian
Industry
Eligibility
0 Years and older
Enrollment
2,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2035
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Not yet recruiting Not applicable Interventional

The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares

NCT07143188
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
elemental diet (ED)
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Terminated Phase 2 Interventional Results available

Open-label Extension Study of Brazikumab in Ulcerative Colitis

NCT04277546
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Brazikumab Maintenance Dose, Brazikumab Induction Dose
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Chula Vista, California • Lancaster, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Recruiting Early Phase 1 Interventional

68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease

NCT07273188
View directory record Official record
Conditions
Crohn's Disease, Intestinal Fibrosis, Inflamatory Bowel Disease, Intestinal Strictures Related to Crohn´s Disease
Interventions
Ga68-FAPI-46
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

NCT01155362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Terminated Phase 4 Interventional

Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)

NCT00205062
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
PET-CT
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 23, 2026, 3:17 PM EDT
Recruiting Not applicable Interventional

Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)

NCT06784323
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Catered diet, Diet guidance sessions, Dietary counseling, Feedback sessions
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
16 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 23, 2026, 3:17 PM EDT
Terminated Phase 1 Interventional

Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

NCT00316550
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
AV608
Drug
Lead sponsor
Avera Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2008 · Synced Oct 23, 2026, 3:17 PM EDT